Related Experiment Video
Updated: Aug 17, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Novel therapeutics in adult malignant brain gliomas
Michele Reni1, Elena Mazza, Alicia Tosoni
1Department of Oncology, San Raffaele H. Scientific Institute via Olgettina 60, 20132 Milan. reni.michele@hsr.it
Abstract:
Malignant gliomas are the most frequent and most malignant intracranial neoplasms. In spite of extensive clinical trials and irrespective of aggressive surgery, radiotherapy and chemotherapy, the outcome is very poor and limited progress has been made in the last three decades. Several innovative targeted molecular therapies that are tailored to deregulate the signalling pathways involved in malignant progression have opened new and challenging treatment opportunities and offer hope for an improved outcome in the future. Furthermore, in the field of conventional cytotoxic agents, new drugs or combinations are continuously investigated, widening the therapeutic armamentarium. This paper reviews this rapidly evolving field, focuses on the results of the use of these agents in clinical trials and discusses the main methodological challenges that need to be dealt with before relevant progress in the outcome of malignant gliomas can be yielded.
Insights
Malignant gliomas remain challenging brain tumors despite advances. This review explores novel molecular therapies and conventional agents, highlighting clinical trial results and future research needs for improved outcomes.
Area of Science:
- Neuro-oncology
- Cancer therapy
- Molecular biology
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Current treatments (surgery, radiotherapy, chemotherapy) show limited efficacy.
- Significant progress in outcomes has not been achieved over the past 30 years.
Purpose of the Study:
- To review the evolving landscape of malignant glioma treatment.
- To focus on targeted molecular therapies and novel cytotoxic agents.
- To discuss clinical trial outcomes and methodological challenges.
Main Methods:
- Literature review of recent clinical trials.
- Analysis of targeted molecular therapies.
- Evaluation of conventional cytotoxic agents and combinations.
Main Results:
- Innovative targeted molecular therapies offer new treatment avenues.
- Ongoing investigation of new drugs and combinations for conventional therapy.
- Clinical trials provide insights into efficacy and challenges.
Conclusions:
- Targeted therapies hold promise for improved malignant glioma outcomes.
- Addressing methodological challenges is crucial for future progress.
- Continued research is essential to overcome treatment limitations.
